ArticleJournal of veterinary internal medicine2026
Efficacy of monotherapy with zonisamide and proposed reference interval in dogs with epilepsy: a cohort of 207 dogs (2011-2021).
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZonisamide (ZNS) has become a popular antiseizure medication (ASM) to treat epilepsy in dogs. Dose adjustments based on plasma ZNS concentrations facilitate management, but efficacy evidence is limited. No reference interval (RI) is established in dogs. HYPOTHESIS/
objectivesTo assess ZNS efficacy and establish an RI for dogs with epilepsy. ANIMALS: Two hundred seven dogs with non-structural epilepsy received ZNS monotherapy, with samples submitted for therapeutic drug monitoring (TDM).
methodsIn this retrospective observational study, ZNS information was collected from the TDM data record library between November 2011 and May 2021. Exclusion criteria were structural epilepsy, receiving other ASMs, dogs' age >6 years, or a duration of ZNS <3 months. Zonisamide response was assessed as described in the International Veterinary Epilepsy Task Force (IVETF) consensus. Plasma ZNS concentrations from responders (categories 1 [seizure freedom] and 2 [partial response]) were evaluated at the established RI.
resultsTwo hundred seven dogs could be assigned to IVETF response categories 1-3. The proportion of responders (59%, n = 123), including categories 1 (29%) and 2 (30%), was higher than non-responders (category 3, 41%, n = 84; P < .01). Based on the responders, an RI of 10-55 μg/mL is proposed. CONCLUSIONS AND CLINICAL IMPORTANCE: This study demonstrated that ZNS monotherapy is effective for treatment of non-structural epilepsy. The proposed RI, 10-55 μg/mL, is a broader range than that in human medicine, 10-40 μg/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.